Wake Forest Univ Baptist Med Ctr — research payments reported

By program year

2 rows

Year	Kind	Amount	Payments
2020	Research	$197,991	24
2019	Research	$106,854	16

Breakdown

Who paid Research payments · program years 2019–2020

AstraZeneca Pharmaceuticals LP $210,861 26 payments
Astellas Pharma Global Development $44,643 8 payments
AstraZeneca AB $25,141 2 payments
AstraZeneca UK Limited $24,200 4 payments

Studies the money was for Research payments · program years 2019–2020

A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia $98,829 4 payments
An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction (HFpEF) Short Title DETERMINE-preserved Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with preserved ejection fraction $33,358 4 payments
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3ITD AML $26,078 3 payments
A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. $25,141 2 payments
The CHRONICLE Study is a multi center non interventional prospective cohort study of adults with severe asthma who do not achieve control with high dose inhaled corticosteroid ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibody therapy $18,898 1 payment
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of the Flt3 Inhibitor Gilteritinib Administered As Maintenance Therapy Following Allogeneic Transplant for Patients With Flt3/Itd Aml $18,565 5 payments
AMETHYST Congestive Heart Failure CHF Heart Failure Therapy Area Cardiovascular, Renal and Metabolism $12,713 2 payments
PONENTE A Multicenter Open-label Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma on High Dose Inhaled Corticosteroid plus Long-acting B2 Agonist and Chronic Oral Corticosteroid Therapy $12,307 4 payments
Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic Head and Neck Cancer $11,590 2 payments
A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. $10,558 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.